141 related articles for article (PubMed ID: 10574259)
1. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
Regele S; Kohlberger P; Vogl FD; Böhm W; Kreienberg R; Runnebaum IB
Br J Cancer; 1999 Oct; 81(4):702-4. PubMed ID: 10574259
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
3. The significance of p53 autoantibodies in the serum of patients with breast cancer.
Willsher PC; Pinder SE; Robertson L; Nicholson RI; Ellis IO; Bell JA; Blamey RW; Green JA; Robertson JF
Anticancer Res; 1996; 16(2):927-30. PubMed ID: 8687153
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
[TBL] [Abstract][Full Text] [Related]
5. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
[TBL] [Abstract][Full Text] [Related]
6. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
7. Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors.
Dalifard I; Daver A; Larra F
Anticancer Res; 1999; 19(6B):5015-22. PubMed ID: 10697504
[TBL] [Abstract][Full Text] [Related]
8. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
[TBL] [Abstract][Full Text] [Related]
9. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
11. The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
Mudenda B; Green JA; Green B; Jenkins JR; Robertson L; Tarunina M; Leinster SJ
Br J Cancer; 1994 Jun; 69(6):1115-9. PubMed ID: 8198980
[TBL] [Abstract][Full Text] [Related]
12. P53 autoantibodies in 1006 patients followed up for breast cancer.
Metcalfe S; Wheeler TK; Picken S; Negus S; Jo Milner A
Breast Cancer Res; 2000; 2(6):438-43. PubMed ID: 11056691
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
[TBL] [Abstract][Full Text] [Related]
15. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast.
Sapino A; Bongiovanni M; Cassoni P; Righi L; Arisio R; Deaglio S; Malavasi F
J Pathol; 2001 Jun; 194(2):254-61. PubMed ID: 11400156
[TBL] [Abstract][Full Text] [Related]
17. p53 autoantibodies can be indicative of the development of breast cancer relapse.
Regele S; Vogl FD; Kohler T; Kreienberg R; Runnebaum IB
Anticancer Res; 2003; 23(1B):761-4. PubMed ID: 12680180
[TBL] [Abstract][Full Text] [Related]
18. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
[TBL] [Abstract][Full Text] [Related]
19. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
20. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
